SAN DIEGO—Cancer stem cells, much like cancer's ability to hide itself from the immune system, represent one of the key reasons
cancer can be so hard to eradicate. These cells can go dormant to evade chemotherapy, then activate again at a later time, resulting in treatment resistance
and relapse.

The team will work together for the discovery and development of a new therapeutic compound
that can inhibit RNA editing. Dr. Catriona Jamieson, associate professor of medicine and chief of the Division of Regenerative Medicine at UC San Diego, and
her group have demonstrated that in chronic myeloid leukemia and other blood cancers, uncontrolled RNA editing helps cancer stem cells self-renew, which in
turn creates more malignant cells.

“The problem with leukemia is that in many cases while we can control the
symptoms of disease, we can’t completely eradicate it because current therapies don’t block cancer stem cell self-renewal. Enhanced RNA editing
is like a cancer stem cell engine, and with this collaboration we want to turn that engine off,” said Jamieson, who is also deputy director of the
Sanford Stem Cell Clinical Center and director of stem cell research at UC San Diego Moores Cancer Center. “We’re very fortunate to have this
opportunity to work completely in step with a highly adept, dynamic company to take the RNA editing target idea from design to delivery of a new therapy that
may prevent cancer relapse.”

This collaboration is part of GlaxoSmithKline's Discovery Partnerships with
Academia (DPAc) program, which was launched as an independent unit in 2010. The goal of DPAc is to advance promising research into drug discovery and
development, in the hopes of bringing new treatments to patients. Each project is supported by a team, with the academic researchers and GSK scientists
sharing data and collaborating. Jamieson will lead the UC San Diego team in this project.

“The GSK DPAc
program is highly selective and works to identify the best academics with the best targets for partnership,” Dr. Carolyn Buser-Doepner, vice present
and global head of DPAc at GSK, commented in a press release. “The UC San Diego collaboration represents several firsts for the DPAc team at GSK
— it is our first target in the emerging area of RNA editing and it is our first bench-to-bedside DPAc collaboration with a California university.
Furthermore, Dr. Jamieson is an ideal collaborator with deep target and disease expertise, a highly productive preclinical research team with access to
clinical samples and the demonstrated ability to translate studies into the clinic.”

“Groundbreaking
research on the basic behavior of stem cells — during human development and in the pathology of disease — has long been one of our strengths at
UC San Diego,” said Dr. Lawrence Goldstein, director of the Stem Cell Program, scientific director of the Sanford Consortium for Regenerative Medicine
and director of the Sanford Stem Cell Clinical Center. “Now, those fundamental studies are paying off, as we begin to apply that information in the
development of new therapies.”